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Abstract
Background: Xenotropic murine leukemia virus-related virus (XMRV) has been found in the prostatic tissue of prostate
cancer patients and in the blood of chronic fatigue syndrome patients. However, numerous studies have found little to no
trace of XMRV in different human cohorts. Based on evidence suggesting common transmission routes between XMRV and
HIV-1, HIV-1 infected individuals may represent a high-risk group for XMRV infection and spread.
Methodology/Principal Findings: DNA was isolated from the peripheral blood mononuclear cells (PBMCs) of 179 HIV-1
infected treatment naı ¨ve patients, 86 of which were coinfected with HCV, and 54 healthy blood donors. DNA was screened
for XMRV provirus with two sensitive, published PCR assays targeting XMRV gag and env and one sensitive, published
nested PCR assay targeting env. Detection of XMRV was confirmed by DNA sequencing. One of the 179 HIV-1 infected
patients tested positive for gag by non-nested PCR whereas the two other assays did not detect XMRV in any specimen. All
healthy blood donors were negative for XMRV proviral sequences. Sera from 23 HIV-1 infected patients (15 HCV
+) and 12
healthy donors were screened for the presence of XMRV-reactive antibodies by Western blot. Thirteen sera (57%) from HIV-
1
+ patients and 6 sera (50%) from healthy donors showed reactivity to XMRV-infected cell lysate.
Conclusions/Significance: The virtual absence of XMRV in PBMCs suggests that XMRV is not associated with HIV-1 infected
or HIV-1/HCV coinfected patients, or blood donors. Although we noted isolated incidents of serum reactivity to XMRV, we
are unable to verify the antibodies as XMRV specific.
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Introduction
Xenotropic murine leukemia virus-related virus (XMRV) is a
gammaretrovirus first discovered in the cancer-associated stroma
of prostate cancer patients in 2006 [1]. More recently, XMRV
DNA and infectious virions were detected in the peripheral blood
mononuclear cells (PBMCs) of patients with chronic fatigue
syndrome (CFS) [2]. Following these initial reports, numerous
studies have either detected a very low prevalence among subjects
or no XMRV at all, even in relatively large cohorts [3–16].
According to several studies, detection of XMRV in human
specimens may be due in part to contamination of laboratory
reagents or tissues with infected cell lines or murine DNA [17–24].
Therefore, inconsistent detection of XMRV between laboratories
may be attributable to differences in the reagents used for
screening for XMRV and to differences in specimen handling
procedures. Additionally, it is possible that inconsistent detection
of XMRV may be partly due to the unknown distribution of the
virus in the human population.
XMRV may be more prevalent in the human immunodefi-
ciency virus type 1 (HIV-1) infected population as the virus may be
transmitted through the same routes as HIV-1. The ability of
XMRV to infect PBMCs and its relatedness to lymphotropic
mouse retroviruses suggest parenteral routes of infection, including
blood transfusion and intravenous drug use [1,2,25,26]. Sexual
transmission has been suggested by the finding that a factor
present in semen increases XMRV infectivity, and by the presence
of XMRV RNA in prostatic secretions [27]. Furthermore,
intravenous inoculation of Indian rhesus macaques with XMRV
demonstrated persistent infection of the reproductive organs,
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findings indicate that individuals at risk for exposure to HIV-1
may also be at risk for exposure to XMRV.
The HIV-1 infected host may provide an immunological
environment propitious for XMRV replication and spread. Apart
from the overall deterioration of the immune system resulting
largely from the depletion of CD4+ T cells (reviewed in [28]),
HIV-1 encodes accessory proteins that antagonize innate antiviral
host proteins shown to restrict XMRV replication, such as several
members of the APOBEC3s and tetherin/BST-2 [29–35]. Thus,
HIV-1 infected persons may potentially accommodate for XMRV
replication due to suppressed immunological defenses on both
systemic and cellular levels.
Based on evidence suggesting common transmission routes
between HIV-1 and XMRV, and the ability of HIV-1 to
neutralize immune components shown to restrict XMRV
replication, we hypothesized that the prevalence of XMRV
among HIV-1 infected patients may be elevated compared to
healthy blood donors. In this study, we used three sensitive
polymerase chain reaction (PCR) assays to screen for the presence
of XMRV DNA in the PBMCs of HIV-1 infected patients, HIV-
1/HCV coinfected patients, and blood donors. To increase our
potential for detecting XMRV DNA in patient specimens, we used
PCR assays that had been previously characterized and shown to
be capable of detecting low levels of viral DNA [2,36]. We also
screened sera from a fraction of the HIV-1 and HCV infected
patients, and uninfected individuals for the presence of XMRV-
reactive antibodies.
Methods
Ethics statement
The Committee for the Protection of Human Subjects at the
University of Texas Health Science Center approved the use of the
PBMCs and sera for the purposes of the present study. All patient
volunteers provided written informed consent. The Institutional
Review Board of Baylor College of Medicine provided concurrent
approval of the studies.
Patient specimens
A total of 179 HIV-1 infected patients representing a wide range
of CD4
+ T cell counts and HIV-1 viral loads were selected for
XMRV screening. Eighty six of these patients were also infected
with HCV. Tests used to diagnose patients with HIV-1 infection
included the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test
(Roche Diagnostics, Indianapolis, IN), the TRUEGENE HIV-1
Genotyping Kit (Siemens Healthcare Diagnostics, Inc., Tarry-
town, NY), the GS HIV-1 Western Blot Kit (Bio-Rad Laborato-
ries, Redmond, WA), and the Advia Centaur EHIV (Siemens
Healthcare Diagnostics, Tarrytown, NY). Tests used to diagnose
patients with HCV infection included the COBAS AmpliPrep/
COBAS TaqMan HCV Test (Roche Diagnostics, Indianapolis,
IN), the VERSANT HCV Genotype (LiPA) 2.0 Assay (Siemens
Healthcare Diagnostics, Inc., Deerfield, IL), and the Advia
Centaur HCV Immunoassay (Siemens Healthcare Diagnostics,
Tarrytown, NY). All subjects were patients of the Thomas Street
Health Center, which is an urban clinic for HIV-1 infected
indigent persons run by the Harris County Hospital District in
Houston, Texas. Blood was collected in EDTA vacutainers and
PBMCs were isolated and stored in liquid nitrogen within 8 hours
of collection according to the HIV/AIDS Network Coordination
(HANC) PBMC Processing Standard Operating Procedure. In
preparation for DNA isolation, the PBMC specimens were stored
at 280uC (less than one month). All HIV-1 infected patients were
antiretroviral treatment naı ¨ve at the time of blood collection. A
total of 54 healthy blood donors from the Gulf Coast Regional
Blood Center were randomly selected for XMRV screening. As
with the HIV-1 infected patient specimens, PBMCs were isolated
within 8 hours of blood collection and were stored at 280uC until
the time of DNA extraction (less than 1 month).
Cell culture
The LNCaP, clone FGC human prostate carcinoma cell line
(ATCC no. CRL-1740), was used to produce XMRV stock and
for antigen in Western blot to screen for XMRV-reactive
antibodies in patient sera. Either the LNCaP cell line or the
PNT1A immortalized human prostate epithelial cell line (see
[37,38]) was used to generate sensitivity controls for PCR. The
LNCaP and PNT1A cell lines were cultured in RPMI medium
1640 (Invitrogen) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin (Invitrogen), and were propagated at
37uC with 5% CO2.
The R187 hybridoma cell line (ATCC no. CRL-1912, [39]) was
used to generate the rat anti-spleen focus-forming virus (SFFV)
p30 monoclonal antibody (mAb) that cross-reacts with XMRV
p30. R187 cells were cultured in RPMI medium 1640 (Invitrogen)
supplemented with 4.5 g/L D-glucose, 2.383 g/L HEPES buffer,
L-glutamine, 1.5 g/L sodium bicarbonate, 110 mg/L sodium
pyruvate, 0.05 mM b-mercaptoethanol, 100 U/ml penicillin,
100 mg/ml streptomycin, and 10% heat-inactivated FBS. Cell
concentrations were maintained between 1610
5 and 1610
6 per
ml, and the conditioned media was harvested every 3 days.
Conditioned media was passed through a 0.22 mm syringe filter
(BD Biosciences) and stored at 280uC.
Patient PBMCs preserved in liquid nitrogen to be activated
prior to PCR screening were thawed at 37uC, washed with 9 ml of
RPMI medium 1640 supplemented with 10% heat-inactivated
FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin, and re-suspended in 10 ml of the same medium with
1 mg/ml PHA (Sigma-Aldrich, St. Louis, MO). PBMCs were
cultured with PHA at 37uCi n5 %C O 2 for 3 days, and then
moved to the same base medium with 20 U/ml of IL-2 in place of
PHA. After culturing for 4 days with IL-2, the PBMCs were
collected for DNA extraction.
DNA isolation
Genomic DNA was prepared from PBMCs using the QIAamp
DNA Mini Kit (Qiagen) according to the manufacturer’s
instructions. DNA extractions were performed in a human tissue
processing laboratory devoid of cloned XMRV or in vitro-
XMRV-infected cell lines, using materials and reagents that had
minimal contact with other laboratories. DNA specimens were
stored at 220uC directly following isolation, in a room free of
amplified or cloned DNA.
To verify the integrity of isolated DNA, the CCR5 gene was
amplified using a modified version of a previously-described PCR
protocol [40]. The 25 ml PCR mixtures contained: 2.5 ml
GeneAmp 106 PCR Gold Buffer (Applied Biosystems), 1 mM
MgCl2, 27 pmoles of primer CCR5c (59-CAA AAA GAA GGT
CTT CAT TAC ACC-39), 27 pmoles of primer CCR5d (59-CCT
GTG CCT CTT CTT CTC ATT TCG-39), 0.4 mM dNTPs,
and one unit AmpliTaq Gold polymerase (Applied Biosystems).
Thermocyling conditions were identical to the original protocol.
PCR detection of XMRV
Two previously-described, non-nested oligonucleotide primer
sets targeting both XMRV gag and env and one previously-
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were used to screen specimens for XMRV DNA (Table 1) [2,36].
The nested env PCR assay was performed according to the protocol
described previously, using 650 ng of template DNA [36]. All
specimens were tested in triplicate with the nested env PCR assay.
The non-nested env and gag PCR assays were modified from the
original protocols. A final PCR reaction volume of 50 ml contained:
250 ng DNA, 5 ml GeneAmp 106 PCR Gold Buffer (Applied
Biosystems), 2.5 mM MgCl2,8 0 0 mM dNTPs, 0.3 mM of each
forward and reverse primer, and 1.5 units of AmpliTaq Gold DNA
polymerase (Applied Biosystems). Thermocycling conditions were
as described in the original protocols [2]. All specimens were tested
in triplicate with both non-nested PCR assays. All PCR reagents
were mixed in a separate room, free of amplified or cloned DNA,
under a containment hood that was subjected to ultra violet (UV)
light before and after each round of PCRs. Sensitivity controls
comprising DNA isolated from cells infected in vitro with XMRV
diluted in DNA from uninfected cells were generated as described
previously, with the exception that PNT1A cells (being more easily
cultured) were used in place of LNCaP cells for a portion of the
controls [36]. Each set of master mixes for each PCR assay used in
XMRV screening was tested for sensitivity and nucleic acid
contamination. Master mixes were considered adequately sensitive
only if they were able to detect XMRV provirus from one infected
cell diluted in 1610
4 uninfected cells in three of three samples using
either 250 ng (non-nested PCR assays) or 650 ng (nested env assay)
of DNA template. Master mixes were considered to be free of
XMRV DNA contamination if negative results were obtained using
water in place of DNA template in three of three samples. After
thermocycling, 20 ml of each PCR mixture was electrophoresed
through 1% agarose with ethidium bromide and visualized under
UV light. PCR amplicons near to the expected size, as gauged by
positive controls and molecular weight markers, were purified from
agarose using the QIAEX II GelExtractionKit (Qiagen), according
to the manufacturer’s protocol. Purified amplicons were ligated into
pCR2.1-TOPO using the TOPO TA Cloning Kit (Invitrogen).
Plasmid constructs were used to transform either One Shot TOP10
(Invitrogen), or NEB 10-beta (New England BioLabs) chemically
competent Escherichia coli, isolated with the QIAPrep Spin Miniprep
Kit (Qiagen), and the sequences of the inserted DNA fragments
were determined. A patient-derived XMRV gag sequence was
deposited into GenBank under accession number JN235142.
PCR screening for contaminants
A previously-described PCR assay targeting intracisternal A-
type particle long terminal repeats (IAPs) was used to screen
specimens for murine DNA contamination [17]. All PCR reagents
and conditions were identical to those described previously, with
the exception that 250 ng of DNA template was used in place of
200 ng for screening the PBMC DNA specimens [17]. DNA
isolated from a vial of preserved murine EL4 cells (ATCC
no. TIB-39), kindly provided by Dr. Qizhi C. Yao, was used as a
positive control. DNA from EL4 cells was isolated and stored in a
laboratory separate from both the laboratory where subject
specimens were stored and the laboratory where PCRs were
conducted, in order to minimize chances for contamination.
Sensitivity was determined by screening dilutions of murine EL4
cell DNA in a background of both 200 and 250 ng of LNCaP
DNA. Six picograms was considered to be the mass of DNA in one
murine cell (one cell equivalent). For each master mix used for
screening subject specimens for murine DNA contamination, five
positive controls and three negative controls were included. The
positive controls consisted of PCRs using templates of 60, 6, 0.6,
and 0.06 pg of EL4 DNA in a background of 250 ng LNCaP
DNA, as well as 6 pg of EL4 DNA without background DNA. The
negative controls consisted of PCRs with either water or LNCaP
(both XMRV-infected and uninfected) DNA in place of template
DNA. Following thermocycling, the PCR mixtures were electro-
phoresed through 1.5% agarose with ethidium bromide and were
visualized under UV light.
A previously-described nested PCR assay was used to screen for
the VP62 XMRV plasmid as a contaminant in patient specimens
[36]. The PCR assay amplifies a DNA fragment spanning the
junction between the pCDNA3.1(2) (Invitrogen) multiple cloning
site and the 59 terminus of XMRV strain VP62. This assay was
previously found to be capable of detecting 10 VP62 plasmids
diluted in 600 ng of LNCaP DNA in three of three samples and
one plasmid in the same amount of LNCaP DNA in one of three
samples [36]. Thermocycling conditions for the first-round PCR
were as follows: 95uC for 5 min; 35 cycles of 94uC for 30 sec, 56uC
for 1.5 min, 72uC for 1.5 min; and ending with 72uC for 10 min.
Thermocycling conditions for the second-round reaction were the
same as the first round, with the exception that the annealing
temperature (56uC) was changed to 52uC. DNA specimens were
screened in one reaction using 250 ng of template DNA and in an
additional reaction using 600 ng of template DNA.
Western blot
Rat monoclonal Ab to SFFV p30 generated from the R187
hybridoma cell line was used as a positive control for detection of
XMRV p30 capsid in Western blot [39]. Affinity-purified rabbit
polyclonal antibodies (pAb) to the peptide sequence, DDPEP-
Table 1. Primers used for screening PBMC DNA specimens for XMRV.
Target Ref. Primer Sequence Location
a
XMRV gag [2] Forward 59-ATCAGTTAACCTACCCGAGTCGGAC-39 424–448
Reverse 59-GCCGCCTCTTCTTCATTGTTCTC-39 1132–1154
XMRV env [2] Forward 59- GCTAATGCTACCTCCCTCCTGG-39 5922–5943
Reverse 59-GGAGCCCACTGAGGAATCAAAACAGG-39 6247–6272
XMRV env [36] Forward 59-ACCAGACTAAGAACTTAGAACCTCG-39 5609–5633
Reverse 59-AGCTGTTCAGTGATCACGGGATTAG-39 6472–6496
Forward 59-GAACAGCATGGAAAGTCCAGCGTTC-39 5747–5771
Reverse 59-CAGTGGATCGATACAGTCTTAGTCC-39 6375–6399
aLocation of 59 end of forward primer target site to 39 end of reverse primer target site on XMRV VP62 reference genome (accession no. DQ399707.1).
doi:10.1371/journal.pone.0031398.t001
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gp70 were generated by Open Biosystems, Inc. (Thermo Fisher
Scientific). These antibodies were used as a positive control for
detection of XMRV gp70 in Western blot. To screen serum
specimens for XMRV reactive antibodies, XMRV-infected
LNCaP cells were lysed in buffer containing 50 mM tris-HCl,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1%
sodium dodecyl sulfate (SDS), and the Complete Mini EDTA-free
protease inhibitor cocktail (Roche). Cell lysates were electropho-
resed through 15% Tris-HCl Criterion precast gels (Bio-Rad
Laboratories) and transferred to Amersham Hybond-ECL nitro-
cellulose membranes (GE Healthcare). Membrane sections were
blocked with 5% nonfat dry milk, and incubated with 1:1,000
diluted R187 cell supernatant (anti-CA), anti-XMRV gp70 pAb
(anti-Env), or 1:100 diluted patient serum. After washing,
membranes were incubated with secondary antibodies conjugated
to horseradish peroxidase: rabbit anti-rat IgG (Sigma-Aldrich),
goat anti-rabbit IgG (Santa Cruz Biotechnology), or goat anti-
human IgG (c-chain specific, Sigma-Aldrich). Membranes were
washed again, incubated briefly with Pierce ECL Western Blotting
Substrate (Thermo Scientific) and exposed to HyBlot CL
autoradiography film (Denville Scientific).
Results
PCR validation
Detection of XMRV (and related viruses) with PCR-based
methods has proven to be rather difficult, with reports of low
frequencies of provirus-containing cells [15,36,41] and the
inability to amplify multiple regions of the XMRV genome from
the same specimen [8,25,36]. In order to maximize the probability
of detecting XMRV by PCR in patient specimens that harbor
provirus, we decided to use three different published assays that
have been successful in earlier studies (Table 1). Two non-nested
primer sets developed by Lombardi et al. were shown to be
capable of detecting XMRV gag and env in the PBMCs of chronic
fatigue syndrome patients, whereas a nested PCR assay developed
in our laboratory had been used to detect XMRV env in the
prostatic tissue of prostate cancer patients [2,36]. Prior to
screening patient samples, we tested the sensitivity of the three
primers sets. We found the non-nested env primers capable of
detecting one infected cell diluted in 1610
4 uninfected cells in two
of three samples using 250 ng of template DNA (,4.2610
4 cells,
Figure 1A, top panel). The non-nested gag primers were found to
be capable of detecting the same dilution of infected cells in three
of three samples (Figure 1A, bottom panel). Considerable non-
specific amplification was seen for both assays, especially for gag,
which occasionally included background amplification products
near to the size expected for the target sequence (Figure 1A,
bottom panel, lane 11). The nested env primers were found to be
capable of detecting one infected cell per 1610
5 uninfected cells in
three of three samples using 650 ng of template DNA (,1610
6
cells, Figure 1B). We contend that, when used in combination,
these three PCR assays are likely to detect low levels of XMRV
sequence because they target multiple genes, have a high degree of
sensitivity, and are reported to have been successful.
XMRV DNA in patient PBMCs
To determine whether the prevalence of XMRV is elevated
among HIV-1 infected and HIV-1/HCV coinfected individuals
compared to healthy blood donors, we screened for XMRV gag
and env genes in DNA isolated from the PBMCs of 179 HIV-1
+
individuals, including 86 coinfected with HCV, and in DNA from
54 healthy blood donors. Each DNA specimen was screened by
PCR in triplicate with each of the three primer sets listed in
Table 1. Consistent with the original protocols for each assay,
250 ng of DNA template was used for the non-nested PCRs,
whereas 650 ng of template was used for the nested env PCR. We
found that both primers sets targeting the env gene produced a few
non-specific amplification products, but rarely any that were of the
expected size for the target sequence (Figure 2A, top panel;
Figure 2B). The few products that were of the expected size were
cloned and sequenced but found to be human chromosomal
sequence artifacts, i.e. bands in Figure 2A, top panel, lanes 5–7.
The non-nested gag primers were found to produce many non-
specific amplification products that were frequently near to the
expected size for the target sequence (Figure 2A, bottom panel).
We cloned and sequenced most non-nested gag PCR products
close to the expected size. We were unable to clone a few PCR
amplicons, which produced exceedingly-faint bands when ob-
served on an agarose gel. All successfully cloned products were not
XMRV proviral DNA sequences with one exception (Figure 2A,
bottom panel, lane 14). The expected 731 nucleotide gag product
(GenBank accession no. JN235142) from one of three PCR
replicates for HIV-1/HCV coinfected patient 103219 was found
to be identical to the sequence of the XMRV plasmid clone, VP62
Figure 1. Sensitivity analysis of XMRV PCR assays. PCR products
were analyzed on agarose gels containing ethidium bromide. (A) Non-
nested PCR assays targeting the XMRV env gene (top panel) and the
gag gene (bottom panel), and (B) a nested PCR assay targeting the
XMRV env gene were evaluated for their ability to detect either (A)
provirus in XMRV-infected PNT1A cell DNA or (B) provirus in XMRV-
infected LNCaP cell DNA diluted in uninfected cell DNA. Dilutions of
infected cells in uninfected cells are indicated by ratios, i.e. 1:10
4
indicates one infected cell diluted in 10
4 uninfected cells. (m) 100 base
pair molecular weight marker, (H2O) water used in place of DNA
template as a negative control, (u) uninfected PNT1A DNA used as
template for negative control.
doi:10.1371/journal.pone.0031398.g001
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our detection of XMRV in patient 103219 was an artifact of
plasmid contamination, we screened this DNA specimen with a
highly sensitive, nested PCR assay specific to VP62 [36]. No
amplification products were observed in triplicate PCRs using
both 250 and 650 ng of template DNA (data not shown). Patient
103219 tested negative for XMRV by non-nested env PCR, and
although we did observe a light band of the expected size in one of
three PCR replicates of nested env PCR, attempts to clone and
sequence this product were unsuccessful (Figure 2B, lane 13). All
54 blood donors tested negative for XMRV with all three PCR
assays. For these specimens, cloning and sequencing revealed that
all PCR products near to the expected size on an agarose gel were
not XMRV. Negative controls with water in place of DNA were
included with every batch of PCRs and never produced any
amplified DNA products throughout the study. The PCR
screening results for XMRV provirus in the PBMCs of the
patients and donors are summarized in Table 2.
Stimulation and culturing of patient PBMCs was reported to
have increased the sensitivity of the non-nested gag and env PCR
assays for detection of XMRV [42]. Therefore, we stimulated
PBMC specimens from 5 HIV-1 infected patients and from 5
HIV-1/HCV coinfected patients with PHA and IL-2 and cultured
them for a week prior to DNA isolation. We screened for XMRV
in both stimulated and unstimulated PBMCs from each of the 10
patients with all three PCR assays using the same protocol as with
the other 169 patient specimens. All 10 patients tested negative
(data not shown).
Apart from the relatedness of XMRV to murine retroviruses, a
murine retroviral origin for XMRV sequences has been suggested
in recent work by Paprotka et al. [20]. Furthermore, several recent
reports have shown that minute quantities of murine DNA in
subject specimens or laboratory reagents can lead to false-positives
when using PCR-based methods to screen for XMRV [17,21–24].
Therefore, we screened for the presence of murine DNA
contamination using the PCR method described by Oakes et al.
[17]. This PCR assay targets murine retrotransposons (IAPs),
which are estimated to be present at a copy number of
approximately 1610
3 per mouse cell [43,44]. Prior to screening
subject specimens, we tested the sensitivity of the IAP PCR assay.
In our hands, the IAP PCR assay was found capable of detecting
1/100
th of the DNA present in a single mouse cell diluted in a
background of 200 ng of LNCaP cell DNA in three of three
samples (Figure 3A). Using this sensitive assay, we screened a
subset of 38 PBMC DNA specimens from the HIV-1 infected and
HIV-1/HCV coinfected patients, which were selected on the basis
that they were either positive for XMRV by sequencing, or they
produced a PCR band close to the expected size on an agarose gel
by any of the three PCR assays used to screen for XMRV. All 38
specimens tested negative for the presence of IAPs, ruling out
murine DNA contaminants as a source for the XMRV sequence
detected in patient 103219 (Figure 3B). Thus, in 1 of three PCR
assays, 1 of 179 HIV-1
+ patients (1 of 86 HIV-1/HCV coinfected
patients) tested positive for XMRV (in one of three PCR replicates
targeting gag) and all 54 healthy blood donors tested negative. The
minimal detection of XMRV in this cohort is in line with multiple
Figure 2. Screening for XMRV in patient PBMCs by PCR. PCR products were analyzed on agarose gels containing ethidium bromide. (A)
Representative gels for non-nested env (top panel) and non-nested gag (bottom panel) PCRs are shown containing a set of three replicates for each
of 5 HIV-1
+ patient samples. A yellow arrow indicates the sole PCR band, from patient 103219, found to be comprised of XMRV DNA by sequencing.
(B) A representative gel for nested env PCR is shown for the same 5 HIV-1
+ patient samples depicted in (A). Vertical black arrows in (A) and (B) indicate
lanes from patient 103219 containing either (A, bottom panel) a band comprised of XMRV sequence or (B) a band of the expected mobility for the
target sequence. (m) 100 base pair molecular weight marker, (1:10
4) DNA from one infected cell diluted in DNA from 10
4 uninfected cells used as
template for positive control.
doi:10.1371/journal.pone.0031398.g002
Table 2. Summary of XMRV screening results.
Gag PCR Env PCR Anti-XMRV Ab
b
Subjects Status Non-nested Non-nested Nested Gag Env
Patients HIV-1
+, HCV
2 0/93
a 0/93 0/93 5/8 0/8
HIV-1
+, HCV
+ 1/86 0/86 0/86 7/15 1/15
Donors HIV-1
2, HCV
2 0/54 0/54 0/54 6/12 0/12
aFractions are: number of subjects scoring positive/total number of subjects screened.
bAb, antibody.
doi:10.1371/journal.pone.0031398.t002
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cohorts [16,45–50]. Due to the exact match of the XMRV
sequence derived from patient 103219 with the VP62 XMRV
plasmid clone used in our laboratory, and to the inability of the
two other PCR assays to produce clonable amplicons of the
expected size, we cannot conclude that DNA from patient 103219
harbored either XMRV provirus or a trace amount of VP62
plasmid contamination that was missed by the VP62 plasmid-
specific nested PCR assay. The results of the PCR screen for
XMRV do not support an association between XMRV and HIV-
1 or HCV infections.
XMRV-reactive antibodies in sera
To further search for evidence of XMRV in the HIV-1 infected
and HIV-1/HCV coinfected patients, we screened for the
presence of XMRV-reactive antibodies in 23 of the 179 HIV-1
+
and HIV-1
+/HCV
+ subjects and in 12 additional healthy blood
donors. The 23 HIV-1
+ (15 HCV
+) patients to be tested for
XMRV-reactive antibodies were chosen if either non-nested gag or
env PCR amplified a product near to the expected mobility on
agarose. Equivalent amounts of whole-cell lysate from uninfected
and XMRV VP62-infected LNCaP prostate carcinoma cells were
used as antigen for testing sera from each patient by immuno-
blotting. Signals due to background reactivity signify similar levels
of proteins present for both uninfected and XMRV-infected
LNCaP cell lysates (Figure 4). Interestingly, we obtained signals
from 13 of the 23 patient sera on XMRV-infected cell lysate
corresponding to the mobility of either the capsid or Env proteins
that were not present for uninfected cell lysate (Figure 4A and
Figure S1). Five of eight sera from HIV-1
+ patients were reactive
to XMRV whereas 8 of 15 sera from HIV-1
+/HCV
+ patients
were reactive (Table 2). Of the 13 XMRV-reactive sera, 12
contained capsid-reactive antibodies, and one contained Env-
reactive antibodies (Table 2). Reactivity to XMRV capsid was
observed for patient 103219 (Figure 4A). Similar to the HIV-1
+
and HIV-1
+/HCV
+ patient sera, reactivity to XMRV was seen for
6 of the 12 healthy blood donors (Figure 4B and Figure S2). For
the healthy blood donors, reactivity was only observed for XMRV
capsid (Table 2). The greater ability to detect capsid-reactive
antibodies compared to Env-reactive antibodies has been reported
previously for plasma from healthy donors and prostate cancer
and chronic fatigue syndrome (CFS) patients [5]. Although these
data are suggestive of infection, without serum from a confirmed
XMRV-infected individual, it is unclear whether reactivity from
these 13 patient sera represents a true adaptive immune response
against XMRV or is simply due to the presence of cross-reactive
antibodies.
Discussion
We screened DNA isolated from the PBMCs of 179 HIV-1
infected patients, including 86 coinfected with HCV, and 54 blood
donors for the presence of XMRV provirus. Only one study
participant (HIV-1
+/HCV
+) tested positive for XMRV gag
sequence in our PCR screen despite the use of three sensitive,
published assays that have reportedly been successful at detecting
XMRV in different human cohorts [2,36]. The low frequency of
XMRV detected in this study is in line with other reports in which
no XMRV was detected in separate HIV-1 infected cohorts
[16,45–50]. Notably, all but one [49] study searching for XMRV
in HIV-1 infected cohorts to date have screened for the virus in the
blood or in constituents of the blood. While the agreement in
results among reports regarding the prevalence of XMRV in HIV-
1 infected cohorts may indicate that XMRV is largely absent from
this population as a whole, it is also possible that XMRV resides
primarily in a cellular compartment other than blood. On this
note, it is important to point out that all but a few [2,5,25] reports
on screens for XMRV in the blood or in blood constituents were
unable to detect the virus [3,4,12,13,16,45–48,50–52]. Compar-
atively, more studies detect XMRV, at least at a low prevalence
[1,8,11,14,15,36,41,53,54], than those that do not [6,9,10,49,51],
when non-blood tissue specimens are screened. As most reports on
screens for XMRV in non-blood-derived specimens pertain to
prostate cancer cohorts, it is unclear whether disease status or the
type of tissue screened is the main determinant for detection of the
virus. A clue may be provided in a recent report on the kinetics
and dissemination of XMRV in Indian rhesus macaques after
intravenous inoculation [26]. In that study, XMRV provirus
became undetectable in macaque PBMCs after only one month
post-inoculation, whereas provirus could be detected from other
macaque tissues throughout the 291 day duration of the study
[26]. If XMRV provirus is cleared from the blood one month after
infection of humans, then the blood (or its constituents) is not a
reliable tissue compartment to screen when attempting to establish
the prevalence of the virus.
In light of the difficulty of detecting XMRV, which may be
partially attributable to lack of knowledge regarding tissue tropism
in the human host, it is important to use multiple methods for
screening. This is also important due to the pitfalls and limitations
associated with certain methods. A drawback to employing the use
of sensitive PCR-based techniques over others in screening studies
is the relative ease at which contamination may lead to false-
positives. The single XMRV gag sequence detected in the PBMC
DNA of an HIV-1/HCV coinfected study participant (103219)
was identical to the gag gene of the VP62 XMRV plasmid clone
used in our laboratory, raising the possibility that the patient-
derived sequence represents an artifact of plasmid contamination.
Our triplicate negative PCR controls included in every batch of
Figure 3. Detecting murine DNA by IAP PCR. PCR products were
analyzed on 1.5% agarose gels containing ethidium bromide. (A)
Sensitivity of the IAP PCR assay was determined by performing PCRs on
titrations of EL4 murine cell line DNA in a background of 200 ng LNCaP
DNA. One murine cell equivalent (1 eq) indicates 6 pg of EL4 DNA.
XMRV-infected LNCaP (iLNCaP) and uninfected LNCaP (uLNCaP) were
included as controls. (B) Screening results for 17 HIV-1
+ patient samples.
Arrow points to sample 103219, which tested positive for XMRV by non-
nested gag PCR. (m) 100 base pair molecular weight marker, (EL4) 6 pg
of murine EL4 cell line DNA without a background of human DNA.
doi:10.1371/journal.pone.0031398.g003
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the study. Furthermore, we found no evidence for plasmid
contamination in patient 103219 by nested PCR screening.
However, since the non-nested and nested PCR assays targeting
XMRV env, as well as repeated rounds of the non-nested gag PCR,
were all unable to produce clonable amplicons of the expected
size, we find it difficult to conclude that DNA from patient 103219
contained XMRV provirus.
Antiretroviral drugs used in highly effective anti-HIV-1
combinations have been shown to inhibit XMRV replication in
vitro [55,56]. Since most studies on XMRV in HIV-1 infected
cohorts screened patients treated with antiretroviral medications, it
is possible that the virus had largely been missed in this
demographic [45,46,48–50]. However, our PCR screening for
XMRV was essentially negative, despite having tested a
population that was entirely treatment naı ¨ve. This is in line with
the results of other studies that have screened treatment naı ¨ve
HIV-1
+ subjects and suggests that XMRV may be largely
undetectable in the blood of HIV-1 infected persons regardless
of their treatment status [16,45,47–50].
In light of the minimal detection of XMRV DNA in the PBMCs
of the subjects we tested, it is possible that the screening
Figure 4. XMRV-reactive antibodies in patient and healthy blood donor sera. Representative Western blots using uninfected (u) and XMRV-
infected (i) LNCaP cell lysate as antigen for (A) HIV-1 infected patient sera or (B) healthy blood donor sera, and positive-control antibodies against p30
capsid (anti-CA) and gp70 SU (anti-Env). (A) Vertical arrows indicate lanes in which patient sera displayed reactivity to either XMRV capsid (left arrow,
103219) or XMRV envelope (right arrow, 103246). (B) Vertical arrows indicate lanes in which blood donor sera displayed reactivity to XMRV capsid (all
four donors on the blot shown). Protein mobilities are indicated in kiloDaltons.
doi:10.1371/journal.pone.0031398.g004
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detect low levels of provirus that may have been present. We find
this unlikely due to our use of three different PCR assays that have
been shown to be very sensitive and effective at detecting XMRV
in patient specimens, and that target different locations on the viral
genome (Table 1). For the non-nested PCR assays, however, it was
reported that sensitivity for detecting XMRV in PBMCs could be
increased if the PBMCs are stimulated with PHA and cultured in
IL-2-containing media prior to PCR [42]. Despite stimulating and
culturing the PBMCs of 10 HIV-1
+ patients (5 HCV
+) we found
no evidence of XMRV infection upon PCR screening with any of
the three assays.
We found that the non-nested gag PCR assay amplified a stretch
of human genomic sequence that is almost precisely the same
length as the intended proviral target sequence, leading to a high
rate of false-positive PCR products when viewed on an agarose
gel. When testing patient DNA with the gag PCR assay using the
HotStart-IT FideliTaq polymerase (Affymetrix), which was used in
the original protocol by Lombardi and colleagues, we still
observed amplification of human genomic sequence of the length
expected for the proviral target sequence (data not shown).
Our screen of sera from a subset of 23 of the HIV-1 infected
patients detected antibodies reactive to proteins of the expected
mobility for XMRV capsid, Gag polyprotein, or Env in 13 (56%)
samples. Interestingly, only one of these 13 sera was reactive to
envelope (Table 2). These results are in general agreement with a
previous report in which only antibodies reactive to XMRV capsid
were detected in the plasma of patients with CFS and prostate
cancer [5]. Seroreactivity to XMRV-infected cell lysate was split
almost evenly between HIV-1
+ and HIV-1
+/HCV
+ patients with
rates of 5/8 (62.5%) and 8/15 (53%) for each, respectively
(Table 2). Similar to the HIV-1
+ patients, we detected antibodies
reactive to XMRV capsid in 6 of 12 (50%) sera from healthy blood
donors, indicating no difference in rates of reactivity to XMRV
between the two groups (Table 2). It is possible that the positive
signals obtained in our immunoblots are due to the presence of
cross-reactive antibodies to proteins encoded by human endoge-
nous retroviruses (HERVs), a large group of which is similar to
MLVs [57,58]. Human IgG reactivity to MLV capsid has been
reported previously [59,60]. In one study, a higher frequency of
individuals with MLV capsid-reactive IgG was seen with HIV-1
infection compared to HIV-1 negative controls, a trend we did not
observe with this cohort [59]. Nonetheless, proteins encoded by
HERVs represent a potential source of antigen that may give rise
to antibodies that are cross-reactive with XMRV. Alternatively,
the XMRV-reactive antibodies detected in the sera of the HIV-1
+
and HIV-1
+/HCV
+ and healthy subjects may have been elicited
by an infection with XMRV or another related exogenous virus
that had been cleared from the PBMCs prior to the time of blood
collection, suggesting a latent infection in a tissue compartment
other than blood as previously found in experimental infection of
rhesus macaques [26]. The lack of an antibody that has proven
specificity for XMRV has led to inconclusive results when using
antibody-based screening methods. For example, it was recently
discovered that human T-cell leukemia virus (HTLV) infection
can elicit antibodies that are cross-reactive with XMRV p15E due
to a homologous region on HTLV gp21 [61].
In conclusion, the results of our screen of HIV-1 infected, HIV-
1/HCV coinfected, and uninfected subjects do not support an
association between XMRV and HIV-1 or HCV infections. Our
report adds to accumulating evidence from other studies
conducted around the world, not only against an association
between these viral infections, but also against the presence of
XMRV in the blood.
Supporting Information
Figure S1 Screen for XMRV-reactive antibodies in HIV-
1
+ and HIV-1
+/HCV
+ patient sera. Western blots using
uninfected (u) and XMRV-infected (i) LNCaP cell lysate as antigen
for patient sera and positive-control antibodies against p30 capsid
(anti-CA) and gp70 SU (anti-Env). Vertical arrows indicate lanes
in which patient sera displayed reactivity to XMRV capsid.
Protein mobilities are indicated in kiloDaltons. Vertical arrows
with asterisks indicate lanes in which signals for XMRV-reactivity
are more apparent with a longer film exposure.
(TIF)
Figure S2 Screen for XMRV-reactive antibodies in
healthy blood donors. Western blots using uninfected (u) and
XMRV-infected (i) LNCaP cell lysate as antigen for healthy blood
donor sera and positive-control antibodies against p30 capsid (anti-
CA) and gp70 SU (anti-Env). Vertical arrows indicate lanes in
which patient sera displayed reactivity to XMRV capsid. Protein
mobilities are indicated in kiloDaltons.
(TIF)
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